Phosphoproteomics of primary human FLT3-ITD+ AML cells treated with gilteritinib

ABSTRACT: Primary human AML cells (newly diagnosed, prior to treatment initation) were obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. AML blasts were treated with FLT3 inhibitor gilteritinib (or DMSO vehicle control) at 10 nM concentration for 6 h, followed by harvest for LC/MS.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Leukocyte, Blood

DISEASE(S): Acute Leukemia

SUBMITTER: Sebastian Koschade  

LAB HEAD: Christian Münch

PROVIDER: PXD034080 | Pride | 2022-08-25

REPOSITORIES: Pride